专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20120269764A1 RBM3 as a Marker for Malignant Melanoma Prognosis 失效
标题翻译： RBM3作为恶性黑素瘤预后的标志物
公开(公告)号：US20120269764A1
公开(公告)日：2012-10-25
申请号：US13201742
申请日：2009-12-17
申请人： Mathias Uhlen , Fredrik Ponten , Karin Jirstrom
发明人： Mathias Uhlen , Fredrik Ponten , Karin Jirstrom
IPC分类号： G01N33/574 , G01N21/64 , C07H21/04 , C07K14/47 , C07K7/06 , C07K16/18 , G01N21/76 , A61K38/20
CPC分类号： G01N33/689 , C07K14/4748 , G01N33/5743
摘要： A method for determining whether a mammalian subject having a malignant melanoma belongs to a first or a second group, wherein the prognosis of subjects of the first group is better than the prognosis of subjects of the second group is provided. The method comprises the steps of: evaluating an amount of RBM3 protein in at least part of a sample earlier obtained from the subject and determining a sample value corresponding to the evaluated amount; comparing said sample value with a predetermined reference value; and if said sample value is higher than said reference value, concluding that the subject belongs to the first group; and if said sample value is lower than or equal to said reference value, concluding that the subject belongs to the second group.
摘要翻译：一种用于确定具有恶性黑素瘤的哺乳动物受试者是否属于第一组或第二组的方法，其中提供了第一组受试者的预后优于第二组受试者的预后。该方法包括以下步骤：评估早期从受试者获得的样品的至少部分中的RBM3蛋白的量，并确定与评估量对应的样品值; 将所述样本值与预定参考值进行比较; 并且如果所述样本值高于所述参考值，则认定所述对象属于所述第一组; 并且如果所述样本值低于或等于所述参考值，则认定所述对象属于所述第二组。

2. 发明授权

US08632984B2 RBM3 as a marker for malignant melanoma prognosis 失效
标题翻译： RBM3作为恶性黑素瘤预后的标志物
公开(公告)号：US08632984B2
公开(公告)日：2014-01-21
申请号：US13201742
申请日：2009-12-17
申请人： Mathias Uhlen , Fredrik Ponten , Karin Jirstrom
发明人： Mathias Uhlen , Fredrik Ponten , Karin Jirstrom
IPC分类号： G01N33/53 , C12N5/07 , A61K39/395 , A61K38/00
CPC分类号： G01N33/689 , C07K14/4748 , G01N33/5743
摘要： A method for determining whether a mammalian subject having a malignant melanoma belongs to a first or a second group, wherein the prognosis of subjects of the first group is better than the prognosis of subjects of the second group is provided. The method comprises the steps of: evaluating an amount of RBM3 protein in at least part of a sample earlier obtained from the subject and determining a sample value corresponding to the evaluated amount; comparing said sample value with a predetermined reference value; and if said sample value is higher than said reference value, concluding that the subject belongs to the first group; and if said sample value is lower than or equal to said reference value, concluding that the subject belongs to the second group.
摘要翻译：一种用于确定具有恶性黑素瘤的哺乳动物受试者是否属于第一组或第二组的方法，其中提供了第一组受试者的预后优于第二组受试者的预后。该方法包括以下步骤：评估早期从受试者获得的样品的至少部分中的RBM3蛋白的量，并确定与评估量对应的样品值; 将所述样本值与预定参考值进行比较; 并且如果所述样本值高于所述参考值，则认定所述对象属于所述第一组; 并且如果所述样本值低于或等于所述参考值，则认定所述对象属于所述第二组。

3. 发明申请

US20110021635A1 RBM3 AS A MARKER FOR BREAST CANCER PROGNOSIS 审中-公开
标题翻译： RBM3作为乳腺癌预后标记
公开(公告)号：US20110021635A1
公开(公告)日：2011-01-27
申请号：US12865936
申请日：2009-02-16
申请人： Mathias Uhlen , Fredrik Ponten , Karin Jirstrom
发明人： Mathias Uhlen , Fredrik Ponten , Karin Jirstrom
IPC分类号： A61K31/135 , C12Q1/02 , G01N33/53 , A61P35/00 , C07K16/18
CPC分类号： G01N33/57415
摘要： The present invention provides means, such as a method, for determining whether a prognosis for a mammalian subject having a breast cancer is better than a reference prognosis. The method comprises the steps of: providing a sample earlier obtained from the subject; evaluating the amount of RBM3 protein present in at least part of said sample, and determining a sample value corresponding to said evaluated amount; comparing the sample value obtained with a reference value associated with said reference prognosis; and, if said sample value is higher than said reference value, concluding that the prognosis for said subject is better than said reference prognosis.
摘要翻译：本发明提供了用于确定具有乳腺癌的哺乳动物受试者的预后是否优于参考预后的方法，例如方法。该方法包括以下步骤：提供从受试者获得的较早样本; 评估存在于所述样品的至少一部分中的RBM3蛋白的量，并确定对应于所述评估量的样品值; 将获得的样品值与与所述参考预后相关的参考值进行比较; 并且如果所述样品值高于所述参考值，则认为所述受试者的预后优于所述参考预后。

4. 发明申请

US20110003854A1 BREAST CANCER TREATMENT AND TREATMENT PREDICTION 审中-公开
标题翻译：乳腺癌治疗和治疗预测
公开(公告)号：US20110003854A1
公开(公告)日：2011-01-06
申请号：US12808589
申请日：2008-12-16
申请人： Fredrik Ponten , Mathias Uhlen , Karin Jirstrom
发明人： Fredrik Ponten , Mathias Uhlen , Karin Jirstrom
IPC分类号： A61K31/138 , G01N33/566 , A61K31/4535 , A61P35/00 , A61N5/10
CPC分类号： G01N33/57415
摘要： The present invention provides a new method and means for determining whether a mammalian subject having a breast cancer is likely to benefit from an endocrine treatment. The method comprise the steps of: providing a sample earlier obtained from said subject; evaluating the amount of CRABP2 protein present in at least part of said sample, and determining a sample value corresponding to said amount; comparing the obtained sample value with a reference value; and, if said sample value is higher than said reference value, concluding that the subject is likely to benefit from an endocrine treatment.
摘要翻译：本发明提供了一种用于确定具有乳腺癌的哺乳动物受试者是否可能受益于内分泌治疗的新方法和手段。该方法包括以下步骤：提供先前从所述受试者获得的样本; 评估存在于所述样品的至少一部分中的CRABP2蛋白的量，并确定对应于所述量的样品值; 将获得的样本值与参考值进行比较; 并且如果所述样品值高于所述参考值，则认为受试者可能受益于内分泌治疗。

5. 发明授权

US08945832B2 Treatment prediction involving HMGCR 有权
标题翻译：治疗预测涉及HMGCR
公开(公告)号：US08945832B2
公开(公告)日：2015-02-03
申请号：US12946934
申请日：2010-11-16
申请人： Mathias Uhlen , Fredrik Ponten , Karin Jirström , Donal J. Brennan
发明人： Mathias Uhlen , Fredrik Ponten , Karin Jirström , Donal J. Brennan
IPC分类号： C12Q1/68 , G01N33/53 , G01N33/574 , C12Q1/26 , G01N33/573
CPC分类号： G01N33/57415 , C12Q1/26 , G01N33/573 , G01N2333/90209
摘要： The present invention provides a method for determining whether a mammalian subject having a breast cancer is likely to benefit from an endocrine treatment, comprising the steps of: providing a sample earlier obtained from said subject; evaluating the amount of HMGCR protein or HMGCR mRNA present in at least part of said sample, and determining a sample value corresponding to said amount; comparing the sample value obtained in step b) with a reference value; and, if said sample value is higher than said reference value, concluding that the subject is likely to benefit from an endocrine treatment. Further, a corresponding method of treatment is provided as well as further methods uses and means which may be employed in connection with breast cancer treatment or treatment prediction.
摘要翻译：本发明提供了一种用于确定具有乳腺癌的哺乳动物受试者是否可能受益于内分泌治疗的方法，包括以下步骤：提供从所述受试者获得的早期样品; 评估存在于所述样品的至少一部分中的HMGCR蛋白或HMGCR mRNA的量，并确定对应于所述量的样品值; 将步骤b）中获得的样本值与参考值进行比较; 并且如果所述样品值高于所述参考值，则认为受试者可能受益于内分泌治疗。此外，提供相应的治疗方法以及可用于与乳腺癌治疗或治疗预测有关的其它方法用途和手段。

6. 发明申请

US20090220975A1 USE OF PROTEIN SATB2 AS A MARKER FOR COLORECTAL CANCER 有权
标题翻译：使用蛋白质SATB2作为颜色癌症的标记
公开(公告)号：US20090220975A1
公开(公告)日：2009-09-03
申请号：US12302248
申请日：2007-06-04
申请人： Mathias Uhlen , Fredrik Ponten
发明人： Mathias Uhlen , Fredrik Ponten
IPC分类号： C12Q1/68 , C12Q1/00 , G01N33/53
CPC分类号： G01N33/57419 , G01N2333/4703
摘要： The invention provides new methods, means and uses in connection with detection, characterization and prognosis of colo-rectal cancer, via the identification of the SATB2 protein as a marker for this cancer type.
摘要翻译：本发明通过鉴定SATB2蛋白作为该癌症类型的标志物，提供了与直肠癌的检测，表征和预后有关的新方法，手段和用途。

7. 发明申请

US20060035265A1 In vitro selection and optional indentification of polypeptides using solid support carriers 审中-公开
标题翻译：使用固体支持载体的多肽的体外选择和任选的鉴定
公开(公告)号：US20060035265A1
公开(公告)日：2006-02-16
申请号：US11242588
申请日：2005-10-03
申请人： Per-Ake Nygren , Mathias Uhlen , Olof Nord
发明人： Per-Ake Nygren , Mathias Uhlen , Olof Nord
IPC分类号： C40B40/08 , C40B40/10
CPC分类号： C12Q1/6811 , C12N15/1075
摘要： The present invention relates to a nucleic acid molecule or a polypeptide that is selected from a method that includes cell-free expression of nucleic acid molecules immobilized on a sold support system. The present invention also relates to a molecular library that has a solid support system having a plurality of nucleic acid molecules immobilized thereon.
摘要翻译：本发明涉及一种核酸分子或多肽，其选自包含固定在已售出的支持体系上的核酸分子的无细胞表达的方法。本发明还涉及具有固定有多个核酸分子的固体支持体系的分子文库。

8. 发明授权

US06210891B1 Method of sequencing DNA 有权
标题翻译： DNA测序方法
公开(公告)号：US06210891B1
公开(公告)日：2001-04-03
申请号：US09269436
申请日：1999-07-06
申请人： Pål Nyren , Mathias Uhlen , Mostafa Ronaghi
发明人： Pål Nyren , Mathias Uhlen , Mostafa Ronaghi
IPC分类号： C12Q168
CPC分类号： C12Q1/6869 , C12Q2565/518 , C12Q2565/301 , C12Q2535/101
摘要： The present invention provides a method of identifying a base at a target position in a single-stranded sample DNA sequence wherein an extension primer, which hybridizes to the sample DNA immediately adjacent to the target position, is provided and the sample DNA and extension primer are subjected to a polymerization reaction in the presence of a deoxynucleotide or dideoxynucleotide, whereby the deoxynucleotide or dideoxynucleotide will only become incorporated and release pyrophosphate if it is complementary to the base in the target position. Release of pyrophosphate is detected enzymatically and pyrophosphate detection enzyme(s) are included in the polymerization step.
摘要翻译：本发明提供了在单链样品DNA序列中鉴定目标位置的碱基的方法，其中提供了与紧邻目标位置的样品DNA杂交的延伸引物，并且样品DNA和延伸引物为在脱氧核苷酸或双脱氧核苷酸的存在下进行聚合反应，由此脱氧核苷酸或双脱氧核苷酸仅在靶位置与碱基互补时才被引入并释放焦磷酸盐。检测到焦磷酸盐的释放，聚合步骤中包括焦磷酸盐检测酶。

9. 发明授权

US5411732A Preparation of fused proteins, antibodies and processes therefore 失效
标题翻译：因此制备融合蛋白，抗体和过程
公开(公告)号：US5411732A
公开(公告)日：1995-05-02
申请号：US130430
申请日：1993-10-01
申请人： Bjorn Lowenadler , Erik Holmgren , Mathias Uhlen , Bjorn Nilsson
发明人： Bjorn Lowenadler , Erik Holmgren , Mathias Uhlen , Bjorn Nilsson
IPC分类号： C07K14/575 , A61K39/00 , C07K14/00 , C07K14/195 , C07K14/31 , C07K14/41 , C07K14/65 , C07K16/00 , C07K16/44 , C07K19/00 , C12N15/00 , C12N15/09 , C12P21/00 , C12P21/02 , C12R1/19 , G01N33/531 , G01N33/577
CPC分类号： A61K39/00 , A61K39/0005 , C07K14/31 , C07K14/65 , C07K16/44 , A61K2039/6068
摘要： A process for preparing antibodies specific for an amino acid sequence which comprises immunizing a mammal with a fused protein comprising said amino acid sequence fused to an immunogenic IgG binding protein is disclosed.
摘要翻译：公开了一种制备对氨基酸序列特异性的抗体的方法，其包括用包含与免疫原性IgG结合蛋白融合的所述氨基酸序列的融合蛋白免疫哺乳动物。

10. 发明申请

US20120034218A1 RBM3 in Colorectal Cancer Prognostics 有权
标题翻译： RBM3在结肠直肠癌预后中的作用
公开(公告)号：US20120034218A1
公开(公告)日：2012-02-09
申请号：US13210816
申请日：2011-08-16
申请人： Mathias Uhlen , Fredrik Pontén , Karin Jirström
发明人： Mathias Uhlen , Fredrik Pontén , Karin Jirström
IPC分类号： A61K39/395 , C12Q1/68 , C07K7/06 , A61K31/7068 , A61P35/00 , C07K14/47 , C40B30/04 , G01N33/566
CPC分类号： C07K16/18 , A61K31/7068 , A61K39/39533 , A61K45/06 , C07K14/4748 , C07K16/3038 , C07K2317/34 , C12Q1/6886 , C12Q2600/106 , C12Q2600/118 , C12Q2600/158 , G01N33/57407 , G01N33/57419 , A61K2300/00
摘要： The present invention provides means, such as a method, for determining whether a mammalian subject having a colorectal cancer belongs to a first or a second group, wherein the prognosis of subjects of the first group is better than the prognosis of subjects of the second group. The method comprises the steps of: evaluating an amount of RBM3 protein or RBM3 mRNA molecule in at least part of a sample earlier obtained from the subject and determining a sample value corresponding to the evaluated amount; comparing said sample value with a predetermined reference value; andif said sample value is higher than said reference value, concluding that the subject belongs to the first group; and if said sample value is lower than or equal to said reference value, concluding that the subject belongs to the second group.
摘要翻译：本发明提供了用于确定具有结肠直肠癌的哺乳动物受试者是否属于第一组或第二组的方法，例如方法，其中第一组受试者的预后优于第二组受试者的预后。该方法包括以下步骤：评估早期从受试者获得的样品的至少部分中的RBM3蛋白或RBM3 mRNA分子的量，并确定对应于评估量的样品值; 将所述样本值与预定参考值进行比较; 并且如果所述样本值高于所述参考值，则认定所述对象属于所述第一组; 并且如果所述样本值低于或等于所述参考值，则认定所述对象属于所述第二组。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式